The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2014
In vitro interaction of eupomatenoid-5 from Piper solmsianum C. DC. var. solmsianum and anti-tuberculosis drugs.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lopes M A, Ferracioli K R C, Siqueira V L D, de Lima Scodro R B, Cortez D A G, da Silva R Z, Cardoso R F
Аннотация
SETTING: Department of Clinical Analysis and Biomedicine, State University of Maringa, Maringa, Parana, Brazil.
OBJECTIVE: To evaluate the in vitro interaction between eupomatenoid-5 (EUP-5), extracted from Piper solmsianum C. DC. var. solmsianum, and first-line anti-tuberculosis drugs against Mycobacterium tuberculosis H₃₇Rv and 20 clinical isolates.
DESIGN: Resazurin drugs combination microtiter assay (REDCA) was performed to determine the interaction between EUP-5 and isoniazid, rifampicin (RMP) and ethambutol (EMB).
RESULTS: Synergism was observed in M. tuberculosis H₃₇Rv and eight clinical isolates with EUP-5+RMP, and in M. tuberculosis H₃₇Rv and 17 clinical isolates with EUP-5+EMB combinations.
CONCLUSION: EUP-5 is a promising compound for further studies on the development of anti-tuberculosis drugs.
OBJECTIVE: To evaluate the in vitro interaction between eupomatenoid-5 (EUP-5), extracted from Piper solmsianum C. DC. var. solmsianum, and first-line anti-tuberculosis drugs against Mycobacterium tuberculosis H₃₇Rv and 20 clinical isolates.
DESIGN: Resazurin drugs combination microtiter assay (REDCA) was performed to determine the interaction between EUP-5 and isoniazid, rifampicin (RMP) and ethambutol (EMB).
RESULTS: Synergism was observed in M. tuberculosis H₃₇Rv and eight clinical isolates with EUP-5+RMP, and in M. tuberculosis H₃₇Rv and 17 clinical isolates with EUP-5+EMB combinations.
CONCLUSION: EUP-5 is a promising compound for further studies on the development of anti-tuberculosis drugs.